Karyopharm Therapeutics (KPTI) Tops Q1 EPS by 7c; Offers FY23 Revenue Guidance

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q1 EPS of ($0.30), $0.07 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $38.7 million versus the consensus estimate of $36.3 million.

GUIDANCE:

Karyopharm Therapeutics sees FY2023 revenue of $145-160 million, versus the consensus of $157.4 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Nvidia and Broadcom earnings: TD Cowen says earnings won’t settle big questions
• Prenetics Global (PRE) Tops Q2 EPS by 18c